Eloxx Pharmaceuticals, Inc. — 2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. Filed March 16, 2018. The company was formed through the December 19, 2017 reverse merger of Sevion Therapeutics and private Eloxx; private Eloxx was the accounting acquirer. Accordingly, the statements principally reflect private Eloxx’s operations, with Sevion included from the merger date.
Business context and development status
Eloxx is a pre-revenue biopharmaceutical company developing therapies for rare diseases caused by premature stop-codon mutations. Its lead candidate, ELX-02, is intended to promote genetic read-through; clinical priorities are cystic fibrosis and cystinosis. The company also described preclinical programs in MPS I, Duchenne muscular dystrophy, and Rett syndrome.
- A Phase 1 single-ascending-dose study in 60 healthy volunteers was completed. A multiple-ascending-dose study in 45 healthy volunteers was ongoing.
- Management targeted mid-2018 U.S. IND and Belgian CTA submissions, and fourth-quarter 2018 first-patient visits for planned Phase 2 cystinosis and cystic fibrosis studies, subject to regulatory review.
Financial and liquidity overview
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense, net | $16.4 million | $9.0 million |
| General and administrative expense | $4.0 million | $0.9 million |
| Total operating expenses | $20.4 million | $9.8 million |
| Net loss | $21.2 million | $9.8 million |
| Net cash used in operating activities | $15.9 million | $8.8 million |
| Net cash provided by financing activities | $38.0 million | $9.7 million |
- Cash and cash equivalents were $24.0 million at year-end, versus $2.2 million a year earlier. Management expected cash to fund current operations through at least the end of the first quarter of 2019; additional financing would be needed thereafter absent other funding or changed spending.
- Current assets were $24.5 million and current liabilities $3.4 million. The balance sheet reported no outstanding debt at year-end; a $2.5 million convertible loan had converted into Series C preferred shares during 2017.
- Fourth-quarter net loss was $10.6 million, operating cash use was $6.3 million, and the company received $16.8 million of net proceeds related to completing its Series C financing. Q4 R&D expense was $8.4 million, including a $3.4 million non-cash Technion-related charge; G&A was $2.2 million and merger-related costs were $0.7 million.
- Gross profit and operating margins are not meaningful because the company had no product revenue.
Material changes, unusual items, and outlook
- Net loss more than doubled year over year. R&D expense rose mainly from the $3.4 million Technion exit-fee provision and increased ELX-02 development costs; G&A rose with personnel, professional services, and $1.3 million of reverse-merger costs.
- The company recorded a $3.4 million R&D expense and corresponding increase to additional paid-in capital in connection with a Technion claim for an exit fee. The parties were discussing a proposed settlement involving shares equal to approximately 2.1% of outstanding shares; the filing does not say that settlement was final.
- Year-end shares outstanding were 27,527,738. The reverse merger and related financings materially changed the share structure; further equity financing could dilute existing holders.
- Management expected expenses and operating losses to increase as it advanced ELX-02 and other candidates. No revenue or profitability guidance was provided.
- In the completed Phase 1 SAD study, the company reported no serious adverse events or deaths, but noted an isolated high-frequency hearing fluctuation outside the normal hearing range in one subject. Preclinical studies found reversible renal toxicity at exposures above intended human doses; kidney and urinary bladder were identified as potential target organs at higher exposures. Longer-duration toxicology work was ongoing.
- ELX-02 had orphan designations for MPS I and Rett syndrome in the U.S., and an EU orphan designation for MPS I. Designation does not constitute marketing approval.
Risks and reporting matters
- The company had accumulated losses of $39.0 million, depended on external financing, and warned that unavailable or unfavorable financing could force delays, reductions, or termination of development programs.
- ELX-02 was the only candidate in clinical development. Clinical efficacy and safety remained unproven; preclinical results may not predict human outcomes, and rare-disease patient recruitment, regulatory review, manufacturing, and competition pose significant risks.
- The company relied on third parties for manufacturing and clinical work, including a single source for a key fermentation-derived raw material. It also identified renal toxicity, Israeli operating and geopolitical exposure, intellectual-property and license obligations, and potential liabilities from Sevion’s legacy business.
- The filing states management considered disclosure controls effective, but management did not assess internal control over financial reporting for 2017 following the merger and operational transition. It planned its initial assessment for year-end 2018 and described remediation work underway. Sevion had previously identified material weaknesses in its controls. The auditor gave an unqualified opinion on the financial statements but did not express an opinion on internal-control effectiveness.
- There was no material pending legal proceeding identified, but the Technion exit-fee matter remained under discussion.
Most important facts for investors to verify
- Whether the planned IND and CTA submissions, Phase 2 trial starts, and Phase 1 MAD completion occurred on schedule, and what the clinical data showed.
- Current cash, operating cash burn, financing needs, and any subsequent equity issuance or dilution relative to the stated Q1 2019 runway estimate.
- Whether the Technion exit-fee claim was settled, the final consideration paid, and any continuing license, milestone, royalty, or transfer restrictions.
- Whether the company completed its 2018 internal-control assessment and addressed identified control needs after the reverse merger.
- Any developments in renal or hearing safety, third-party supply continuity, and potential legacy Sevion liabilities.